about
Sirtuin 1 and aging theory for chronic obstructive pulmonary diseaseOxidative stress and free radicals in COPD--implications and relevance for treatmentReactive oxygen species-activated nanomaterials as theranostic agentsNeu-164 and Neu-107, two novel antioxidant and anti-myeloperoxidase compounds, inhibit acute cigarette smoke-induced lung inflammationNitric oxide and superoxide mediate diesel particle effects in cytokine-treated mice and murine lung epithelial cells--implications for susceptibility to traffic-related air pollutionLack of Effect of Oral Sulforaphane Administration on Nrf2 Expression in COPD: A Randomized, Double-Blind, Placebo Controlled TrialRNAi Screen for NRF2 Inducers Identifies Targets That Rescue Primary Lung Epithelial Cells from Cigarette Smoke Induced Radical StressAn official American Thoracic Society/European Respiratory Society statement: update on limb muscle dysfunction in chronic obstructive pulmonary disease.Mepenzolate bromide displays beneficial effects in a mouse model of chronic obstructive pulmonary disease.Effects of N-acetylcysteine in ozone-induced chronic obstructive pulmonary disease model.Nontypeable Haemophilus influenzae induces sustained lung oxidative stress and protease expression.Inflammation in chronic obstructive pulmonary disease and its role in cardiovascular disease and lung cancer.Oxidative stress-induced mitochondrial dysfunction drives inflammation and airway smooth muscle remodeling in patients with chronic obstructive pulmonary diseaseHyper-osmolarity and calcium chelation: Effects on cystic fibrosis mucus.Systems pharmacology-based approach for dissecting the active ingredients and potential targets of the Chinese herbal Bufei Jianpi formula for the treatment of COPD.Combining systems pharmacology, transcriptomics, proteomics, and metabolomics to dissect the therapeutic mechanism of Chinese herbal Bufei Jianpi formula for application to COPD.System biology analysis of long-term effect and mechanism of Bufei Yishen on COPD revealed by system pharmacology and 3-omics profilingCarbocisteine attenuates TNF-α-induced inflammation in human alveolar epithelial cells in vitro through suppressing NF-κB and ERK1/2 MAPK signaling pathways.Comparative cytoprotective effects of carbocysteine and fluticasone propionate in cigarette smoke extract-stimulated bronchial epithelial cells.Sestrin-2, a repressor of PDGFRβ signalling, promotes cigarette-smoke-induced pulmonary emphysema in mice and is upregulated in individuals with COPD.Clinical management of chronic obstructive pulmonary disease patients with muscle dysfunction.Superiority of pulmonary administration of mepenzolate bromide over other routes as treatment for chronic obstructive pulmonary disease.Integrating Transcriptomics, Proteomics, and Metabolomics Profiling with System Pharmacology for the Delineation of Long-Term Therapeutic Mechanisms of Bufei Jianpi Formula in Treating COPDRole of transcription factors in the pathogenesis of asthma and COPD.Cellular metabolic and autophagic pathways: traffic control by redox signaling.The role of N-acetylcysteine in the management of acute and chronic pulmonary complications of sulfur mustard: a literature review.Oxidation pathway and exacerbations in COPD: the role of NAC.Modelling c-Abl Signalling in Activated Neutrophils: the Anti-inflammatory Effect of SeliciclibRole of Inflammation and Oxidative Stress in the Pathology of Ageing in COPD: Potential Therapeutic Interventions.The eucalyptus oil ingredient 1,8-cineol induces oxidative DNA damage.Bifunctional Drugs for the Treatment of Respiratory Diseases.Alterations of bronchial epithelial metabolome by cigarette smoke are reversible by an antioxidant, O-methyl-L-tyrosinyl-γ-L-glutamyl-L-cysteinylglycine.Dioscorin pre-treatment protects A549 human airway epithelial cells from hydrogen peroxide-induced oxidative stress.Functional, Cellular, and Molecular Remodeling of the Heart under Influence of Oxidative Cigarette Tobacco Smoke.A pharmacodynamic model of Bcr-Abl signalling in chronic myeloid leukaemia.Integration of transcriptomics, proteomics, metabolomics and systems pharmacology data to reveal the therapeutic mechanism underlying Chinese herbal Bufei Yishen formula for the treatment of chronic obstructive pulmonary disease.Management of airway mucus hypersecretion in chronic airway inflammatory disease: Chinese expert consensus (English edition).SIRT1 Activity in Peripheral Blood Mononuclear Cells Correlates with Altered Lung Function in Patients with Chronic Obstructive Pulmonary Disease.Reactive Oxygen Species in Chronic Obstructive Pulmonary Disease.A comparative study of antioxidant-loaded carbon nanoparticles as drug delivery vehicles
P2860
Q26799889-AD716CF3-17E2-4725-A748-BDBE76F86DBDQ26830076-4370A381-DD73-414E-90DA-99827B4E47E7Q26865564-7EEAE65E-7303-4800-9F0D-8729818046DAQ28386473-CFCE5941-FDA5-4ACE-9D3A-CE629C40EC8EQ28393124-86C8E580-21DA-495A-877A-CF09A8C0801BQ28393862-3E07583E-8A9C-4FB0-B451-2396493743A0Q28553458-1EA8A90D-AA91-4E2C-AECD-809BAA08F749Q33901722-D494A905-F409-4A37-BA7D-8ED629D93FFCQ35031623-52187AB7-FE16-406A-9165-6CE87281909AQ35049254-073C1832-8D90-4134-9927-8D052E8F6781Q35203322-09CBE3A1-E92D-4FC9-854B-E2A7E2F08FC9Q35897669-53C38A55-843E-488D-9325-E46104553208Q36024291-11540D39-AC45-4DB1-B31B-8534B6B1BEA3Q36144853-77BCF585-6B15-4148-8703-8E8BB0035FA4Q36365175-8B0729EF-7E72-4617-B909-D04A58DBC9A3Q36710084-BF66318D-F814-4B78-A045-0E796047A782Q36870844-9BA4A260-C147-411F-9E61-759FB48ED37CQ36872129-BF4CF7DE-1CB4-4F59-83F7-5783372D5DB0Q37213580-F349A1C9-2DA8-4A3C-B2FF-1A5A6C2DC76AQ37287430-76493D55-BFAE-4971-88F4-B20693298397Q37528272-AA72E382-2E97-4FC9-B499-06B67264EFF3Q37670228-C07933FD-AAFD-48B0-8668-0CDED6A9A5E9Q37739257-CBFFE328-9E94-499C-BD15-30E97E24CFC9Q38087650-DE5CC515-7728-492C-978E-626795AE9367Q38108973-B00176E5-A5B5-4D7D-854A-3D582309E236Q38233230-66AAE5E5-80B3-4AEF-A5B3-D0004F7ACBA3Q38633304-191CE9B9-3B73-4062-A7B5-EF590158C06EQ38877559-10695AE8-F642-4786-BD15-7C03CFFC6B6CQ38953736-95E736D0-8364-41EF-A711-E407997A7BEAQ38986523-B7A916C8-FA21-4DF0-B84D-0BD49DF21242Q38992596-870C3281-35D7-4AFF-ACCF-3E098C827D64Q38997083-BBA32294-7331-46F4-9E3B-320318C5BD0FQ39168416-5BE69E91-DD33-46FE-8E4C-3C60F469143AQ41229712-76517A8F-C103-41D9-94B0-84697ECD630DQ46854633-77124659-46B0-45BD-B120-98EEBD86444DQ47639229-B6C23317-A367-4A1D-BA03-18A156BEE933Q49415318-CBD691FD-1AB1-499C-AD24-A44B704762CAQ54970037-DA1E4BFC-A01E-42EB-BB7A-CA8BF03884F9Q55268558-9DF6F941-B1B5-4694-9FB0-4EEE92856A56Q59222610-48D8DCCD-F7B3-473A-AC2C-776A5505B24D
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Antioxidant pharmacological therapies for COPD.
@en
Antioxidant pharmacological therapies for COPD.
@nl
type
label
Antioxidant pharmacological therapies for COPD.
@en
Antioxidant pharmacological therapies for COPD.
@nl
prefLabel
Antioxidant pharmacological therapies for COPD.
@en
Antioxidant pharmacological therapies for COPD.
@nl
P2860
P1476
Antioxidant pharmacological therapies for COPD.
@en
P2093
Irfan Rahman
P2860
P304
P356
10.1016/J.COPH.2012.01.015
P577
2012-02-18T00:00:00Z